[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604530":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":108,"centralContacts":113,"locations":124,"responsibleParty":145,"collaborators":147,"id":151,"slug":152,"hasResults":153,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":153,"sex":159,"minAge":160,"maxAge":118,"enrollmentInfo":161,"targetDuration":118,"studyType":164,"phases":165,"briefSummary":167,"conditions":168,"keywords":118,"overallStatus":126,"whyStopped":118,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":180},{"fullName":5,"class":6},"Jonsson Comprehensive Cancer Center","OTHER",[8,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm I (177Lu-PSMA-617)","EXPERIMENTAL","Patients receive 177Lu-PSMA-617 IV, over 1-10 minutes, on day one of each cycle. Cycles repeat every 6 weeks for 2 cycles. 4-6 weeks after completion of 177Lu-PSMA-617 patients receive 68Ga-PSMA-11 IV and undergo PSMA PET\u002FCT scan. Within 4 weeks of the scan, patients receive SBRT, for 1-5 treatments, over 1- 1- days. Treatment is given in the absence of disease progression or unacceptable toxicity. Patients undergo PSMA PET\u002FCT scan and blood sample collection throughout the study.",[13,14,15,16,17],"Drug: Actinium Ac 225 Vipivotide Tetraxetan","Procedure: Biospecimen Collection","Drug: Lutetium Lu 177 Vipivotide Tetraxetan","Procedure: PSMA PET-CT Scan","Radiation: Stereotactic Body Radiation Therapy",{"label":19,"type":10,"description":20,"interventionNames":21},"Arm II (225Ac-PSMA-617)","Patients receive 225Ac-PSMA-617 IV once. 4-6 weeks after completion of 225Ac-PSMA-617 patients receive 68Ga-PSMA-11 IV and undergo PSMA PET\u002FCT scan. Within 4 weeks of the scan, patients receive SBRT, for 1-5 treatments, over 1- 1- days. Treatment is given in the absence of disease progression or unacceptable toxicity. Patients undergo PSMA PET\u002FCT scan and blood sample collection throughout the study.",[13,14,22,16,17],"Other: Gallium Ga 68 Gozetotide",[24,37,46,77,91,99],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","Actinium Ac 225 Vipivotide Tetraxetan","Given IV",[9,19],[30,31,32,33,34,35,36],"225Ac-labeled PSMA-617","225Ac-PSMA-617","225Ac-Vipivotide Tetraxetan","Actinium (225AC) PSMA-617","Actinium Ac 225 PSMA-617","Actinium Ac 225-PSMA-617","VIPIVOTIDE TETRAXETAN ACTINIUM AC-225",{"type":38,"name":39,"description":40,"armGroupLabels":41,"otherNames":42},"PROCEDURE","Biospecimen Collection","Undergo blood sample collection",[9,19],[43,44,45],"Biological Sample Collection","Biospecimen Collected","Specimen Collection",{"type":6,"name":47,"description":27,"armGroupLabels":48,"otherNames":49},"Gallium Ga 68 Gozetotide",[19],[50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76],"(68)Ga labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC","(68)Ga-labeled Glu-urea-Lys(Ahx)-HBED-CC","(68)Ga-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC","(68)Gallium-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC","(68Ga)Glu-urea-Lys(Ahx)-HBED-CC","68Ga-DKFZ-PSMA-11","68Ga-HBED-CC-PSMA","68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC","68Ga-PSMA","68Ga-PSMA-11","68Ga-PSMA-HBED-CC","[68Ga] Prostate-specific Membrane Antigen 11","[68Ga]GaPSMA-11","AAA 517","AAA-517","AAA517","Ga PSMA","Ga-68 labeled DKFZ-PSMA-11","Ga-68 labeled PSMA-11","GA-68 PSMA-11","Gallium Ga 68 PSMA-11","Gallium Ga 68-labeled PSMA-11","GALLIUM GA-68 GOZETOTIDE","Gallium-68 PSMA","Gallium-68 PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC","GaPSMA","PSMA-HBED-CC GA-68",{"type":25,"name":78,"description":27,"armGroupLabels":79,"otherNames":80},"Lutetium Lu 177 Vipivotide Tetraxetan",[9],[81,82,83,84,85,86,87,88,89,90],"177Lu-labeled PSMA-617","177Lu-PSMA-617","AAA 617","AAA-617","AAA617","Lu177-PSMA-617","Lutetium Lu 177-PSMA-617","LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN","Lutetium-177-PSMA-617","Pluvicto",{"type":38,"name":92,"description":93,"armGroupLabels":94,"otherNames":95},"PSMA PET-CT Scan","Undergo PSMA PET\u002FCT scan",[9,19],[96,97,98],"PET-CT (PSMA)","Prostate-specific Membrane Antigen PET-CT","PSMA PET-CT",{"type":100,"name":101,"description":102,"armGroupLabels":103,"otherNames":104},"RADIATION","Stereotactic Body Radiation Therapy","Undergo SBRT",[9,19],[105,106,107],"SABR","SBRT","Stereotactic Ablative Body Radiation Therapy",[109],{"name":110,"affiliation":111,"role":112},"Amar Kishan","UCLA \u002F Jonsson Comprehensive Cancer Center","PRINCIPAL_INVESTIGATOR",[114,120],{"name":115,"role":116,"phone":117,"phoneExt":118,"email":119},"Christy Palodichuk","CONTACT","3107942971",null,"cpalodichuk@mednet.ucla.edu",{"name":121,"role":116,"phone":122,"phoneExt":118,"email":123},"Care Felix","310-825-9771","cfelix@mednet.ucla.edu",[125],{"facility":111,"status":126,"city":127,"state":128,"zip":129,"country":130,"countryCode":131,"cosmosGeoPoint":132,"geoPoint":137,"contacts":138},"RECRUITING","Los Angeles","California","90095","United States","US",{"type":133,"coordinates":134},"Point",[135,136],-118.24368,34.05223,{"lat":136,"lon":135},[139,141,143],{"name":115,"role":116,"phone":140,"phoneExt":118,"email":119},"310-825-9775",{"name":121,"role":116,"phone":142,"phoneExt":118,"email":123},"3108259771",{"name":144,"role":112,"phone":118,"phoneExt":118,"email":118},"Amar Kishan, MD",{"type":146,"investigatorFullName":118,"investigatorTitle":118,"investigatorAffiliation":118,"oldNameTitle":118,"oldOrganization":118},"SPONSOR",[148],{"name":149,"class":150},"Novartis Pharmaceuticals","INDUSTRY","100604530","phase-2-alpha-emitting-radionuclide-or-beta-emitting-radionuclide-with-metastasis-directed-stereotactic-body-radiotherapy-for-the-treatment-of-recurrent-oligometastatic-prostate-adenocarcinoma-100604530",false,"NCT07150715","Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma","Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide Combined With Metastasis-Directed Stereotactic Body Radiotherapy for Oligorecurrent Prostate Adenocarcinoma (ANDROMEDA)","ANDROMEDA","Inclusion Criteria:\n\n* Oligorecurrent prostate cancer as determined by the presence of 1-5 asymptomatic lesions outside the prostate or prostate bed identified on PSMA PET\u002FCT by local readers\n* Serum testosterone \\> 150 ng\u002FdL\n* Age ≥ 18 years\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2\n* No indication for urgent or emergent radiation\n* Histological confirmation of prostate adenocarcinoma (histology from original treatment acceptable)\n* White blood cell count ≥ 2.5 × 109\u002FL\n* Platelets ≥ 100 × 109\u002FL\n* Hemoglobin ≥ 9 g\u002FdL\n* Total bilirubin ≤ 1.5 × institutional upper limits of normal (ULN) or up to 3 × ULN if known history of Gilbert's syndrome\n* Alanine aminotransferase or aspartate aminotransferase ≤ 3.0 × ULN or ≤ 5.0 × ULN for patients with liver metastases\n* Glomerular filtration rate creatinine-cystatin C (GFRcr-cys) ≥ 60 mL\u002Fmin 1.73m2 using the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) 2021 equation\n* Serum albumin \\> 3.0 g\u002FdL\n* Partner and patient must use a method of birth control with adequate barrier protection, deemed acceptable by the principal investigator during the study and for 3 months after last study drug administration\n* Ability to understand, and willingness to sign, the written informed consent\n\nExclusion Criteria:\n\n* Patients with neuroendocrine or small cell carcinoma of the prostate\n* Patients with castrate-resistant disease (i.e., prostate specific antigen \\[PSA\\] \\> 0.5 ng\u002FmL with serum testosterone \\\u003C150 ng\u002FdL)\n* Patients who received androgen deprivation therapy or cytotoxic chemotherapy within 6 months of trial enrolment\n* Concurrent systemic therapy for a solid organ malignancy\n* Spinal cord compression\n* Inability to lie flat\n* Known hypersensitivity to components of 177-Lu-PSMA-617 or 225-Ac-Lu-PSMA-617\n* Inadequate renal function of GFRcr-cys \\\u003C 60 mL\u002Fmin 1.73m2 using the CKD-EPI 2021equation\n* Total bilirubin \\> 1.5 × ULN or \\> 3.0 × ULN if known history of Gilbert's syndrome\n* Alanine aminotransferase or aspartate aminotransferase \\> 3 × ULN (or 5 × ULN for patients with known liver metastases)\n* De novo oligometastatic disease","MALE","18 Years",{"count":162,"type":163},107,"ESTIMATED","INTERVENTIONAL",[166],"PHASE2","This phase II trial compares the use of 225Ac-PSMA-617 to 177Lu-PSMA-617, along with stereotactic body radiotherapy for the treatment of prostate cancer that has come back after a period of improvement (recurrent) and that has spread from where it first started (primary site) to multiple other places in the body (oligometastatic). 225Ac-PSMA-617 and 177Lu-PSMA-617 are radioactive drugs. They bind to a protein called a PSMA receptor, which is found on some prostate tumor cells. 225Ac-PSMA-617 or 177Lu-PSMA-617 builds up in these cells and gives off either alpha or beta radiation that may kill them. It is a type of radioconjugate and a type of PSMA analog. Stereotactic body radiation therapy (SBRT) is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body (except the brain). The total dose of radiation is divided into smaller doses given over several days. This type of radiation therapy helps spare normal tissue. Giving 225Ac-PSMA-617 or 177Lu-PSMA-617 and metastasis directed stereotactic body radiotherapy may be effective in treating patients with recurrent, oligometastatic prostate cancer.",[169,170],"Oligometastatic Prostate Adenocarcinoma","Recurrent Prostate Adenocarcinoma","2025-12-15",{"date":173,"type":174},"2025-12-17","ACTUAL",{"date":176,"type":174},"2025-12-12",{"date":178,"type":163},"2031-10-31",{"name":5,"class":6},1]